Payment overview · 2025
General Payments
$9,897.09
62 reported records · 9 companies
Healthcare provider profile · identity verified
Darren M Traub, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BETHLEHEM, PA · NPI 1679602288
Verified facts
What the public records show
CMS Open Payments records show Darren M Traub, D.O. received $9,897.09 in general payments during 2025 across 62 reported records.
Medtronic, Inc. accounted for 47.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$4,742.05 | 47.9% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,453.46 | 24.8% | 21 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,939.21 | 19.6% | 23 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $220.69 | 2.2% | 3 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $173.61 | 1.8% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $168.91 | 1.7% | 2 | 2025 |
| ZOLL Respicardia, Inc. | Unresolved — no canonical attribution shown | $149.92 | 1.5% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $28.17 | 0.3% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $21.07 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,400.00 | 3 |
| Travel and Lodging | $2,901.02 | 9 |
| Food and Beverage | $2,596.07 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $4,435.56 | 6 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $2,161.32 | 16 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $1,514.14 | 7 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $306.49 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $220.69 | 3 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $172.74 | 3 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $166.30 | 1 | 2025 |
Source payment records
|
|||||
| remede System Normalized: remede system |
Device | ZOLL Respicardia, Inc. | $149.92 | 1 | 2025 |
Source payment records
|
|||||
| LM Undivided Normalized: lm undivided |
Device | Philips North America LLC | $146.91 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $125.04 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $125.04 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $107.72 | 8 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $100.55 | 1 | 2025 |
Source payment records
|
|||||
| EMPOWER Leadless Pacemaker System_CRM Normalized: empower leadless pacemaker system crm |
Device | Boston Scientific Corporation | $56.81 | 1 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $48.57 | 1 | 2025 |
Source payment records
|
|||||
| MOMENTUM EL ICD VR Normalized: momentum el icd vr |
Device | Boston Scientific Corporation | $29.47 | 1 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $28.17 | 1 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| INGEVITY+ Normalized: ingevity |
Device | Boston Scientific Corporation | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $15.41 | 2 | 2025 |
Source payment records
|
|||||
| AGILIS Normalized: agilis |
Device | Abbott Laboratories | $9.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 325 | 103 |
| Eliquis | Apixaban | 324 | 95 |
| Flecainide Acetate | Flecainide Acetate | 177 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 169 | 57 |
| Dofetilide | Dofetilide | 164 | 45 |
| Xarelto | Rivaroxaban | 161 | 41 |
| Losartan Potassium | Losartan Potassium | 116 | 33 |
| Atorvastatin Calcium | Atorvastatin Calcium | 107 | 32 |
| Warfarin Sodium | Warfarin Sodium | 100 | 32 |
| Nebivolol Hcl | Nebivolol Hcl | 99 | 24 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 96 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 29 |
| Potassium Chloride | Potassium Chloride | 81 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 77 | 29 |
| Furosemide | Furosemide | 56 | 22 |
| Lisinopril | Lisinopril | 56 | 17 |
| Digoxin | Digoxin | 51 | 18 |
| Atenolol | Atenolol | 48 | 13 |
| Sotalol | Sotalol Hcl | 47 | 15 |
| Ezetimibe | Ezetimibe | 43 | 12 |
| Carvedilol | Carvedilol | 42 | 15 |
| Torsemide | Torsemide | 40 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 23 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Multaq | Dronedarone Hcl | 20 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,897.09 · 62 records | Medtronic, Inc. | ACCOLADE SR, AFX2 Bifurcated Endograft System, AGILIS, AURORA EV-ICD MRI SURESCAN, AVEIR, Acticor 7 VR-T DX, EMBLEM MRI S-ICD, EMPOWER Leadless Pacemaker System_CRM, ENDOCROSS Device, ENSITE, ENSITE PRECISION, FARAPULSE, General - Therapies, INGEVITY+, JOT DX, LM Undivided, Labosys, MICRA, MOMENTUM EL ICD VR, Rhythmia Mapping System, SAPIEN 3 Ultra RESILIA, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Torus Stent Graft System, remede System | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error